��������

Isao Teshirogi became Representative Director and President and CEO in 2008. He has pushed forward with global research and development and expansion of overseas business in Europe and Asia to achieve the goals of the Third Medium-Term Management Plan, and secured the Company’s medium-to-long-term profit foundation through globally competitive drug discovery capabilities and evolution of the Company’s royalty business model. Given the steady achievement of the quantitative targets in the Medium-Term Management Plan, Shionogi Growth Strategy 2020 (SGS2020), which was formulated in FY2014, he carried out an update of SGS2020 in October 2016. As part of that update, he set new quantitative targets from the perspectives of growth, efficiency and shareholder returns. These targets were achieved ahead of schedule, particularly profit targets. Based on these results, we believe that he can make the Company “grow as a drug-discovery based pharmaceutical company,” and therefore we elected him as a Director.